Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.
The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, hist...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3901680?pdf=render |
id |
doaj-7601a06faad3438a8944fa21637befe7 |
---|---|
record_format |
Article |
spelling |
doaj-7601a06faad3438a8944fa21637befe72020-11-25T01:29:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8619410.1371/journal.pone.0086194Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma.Diana MeckbachJürgen BauerAnnette PflugfelderFriedegund MeierChristian BuschThomas K EigentlerDavid CapperAndreas von DeimlingMichel MittelbronnSven PernerKristian IkenbergMarkus HantschkePetra BüttnerClaus GarbeBenjamin WeideThe prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, histological subtype as well as mitotic rate. The mutational rate was 36.7% in patients with disease-free course and 51.7% in those with subsequent distant metastasis (p = 0.031). No difference in overall survival (p = 0.119) but a trend for worse distant-metastasis-free survival (p = 0.061) was observed in BRAF mutant compared to BRAF wild-type patients. Independent prognostic factors for overall survival were tumor thickness, mitotic rate and ulceration. An interesting significant prognostic impact was observed in patients with tumor thickness of 1 mm or less, with the mutation present in 6 of 7 patients dying from melanoma. In conclusion, no significant survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma but an increasing impact of the mutational status was observed in the subgroup of patients with tumor thickness of 1 mm or less. A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies.http://europepmc.org/articles/PMC3901680?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Diana Meckbach Jürgen Bauer Annette Pflugfelder Friedegund Meier Christian Busch Thomas K Eigentler David Capper Andreas von Deimling Michel Mittelbronn Sven Perner Kristian Ikenberg Markus Hantschke Petra Büttner Claus Garbe Benjamin Weide |
spellingShingle |
Diana Meckbach Jürgen Bauer Annette Pflugfelder Friedegund Meier Christian Busch Thomas K Eigentler David Capper Andreas von Deimling Michel Mittelbronn Sven Perner Kristian Ikenberg Markus Hantschke Petra Büttner Claus Garbe Benjamin Weide Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. PLoS ONE |
author_facet |
Diana Meckbach Jürgen Bauer Annette Pflugfelder Friedegund Meier Christian Busch Thomas K Eigentler David Capper Andreas von Deimling Michel Mittelbronn Sven Perner Kristian Ikenberg Markus Hantschke Petra Büttner Claus Garbe Benjamin Weide |
author_sort |
Diana Meckbach |
title |
Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. |
title_short |
Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. |
title_full |
Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. |
title_fullStr |
Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. |
title_full_unstemmed |
Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. |
title_sort |
survival according to braf-v600 tumor mutations--an analysis of 437 patients with primary melanoma. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
The prognostic impact of BRAF-V600 tumor mutations in stage I/II melanoma patients has not yet been analyzed in detail. We investigated primary tumors of 437 patients diagnosed between 1989 and 2006 by Sanger sequencing. Mutations were detected in 38.7% of patients and were associated with age, histological subtype as well as mitotic rate. The mutational rate was 36.7% in patients with disease-free course and 51.7% in those with subsequent distant metastasis (p = 0.031). No difference in overall survival (p = 0.119) but a trend for worse distant-metastasis-free survival (p = 0.061) was observed in BRAF mutant compared to BRAF wild-type patients. Independent prognostic factors for overall survival were tumor thickness, mitotic rate and ulceration. An interesting significant prognostic impact was observed in patients with tumor thickness of 1 mm or less, with the mutation present in 6 of 7 patients dying from melanoma. In conclusion, no significant survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma but an increasing impact of the mutational status was observed in the subgroup of patients with tumor thickness of 1 mm or less. A potential role of the mutational status as a prognostic factor especially in this subgroup needs to be investigated in larger studies. |
url |
http://europepmc.org/articles/PMC3901680?pdf=render |
work_keys_str_mv |
AT dianameckbach survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT jurgenbauer survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT annettepflugfelder survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT friedegundmeier survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT christianbusch survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT thomaskeigentler survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT davidcapper survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT andreasvondeimling survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT michelmittelbronn survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT svenperner survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT kristianikenberg survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT markushantschke survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT petrabuttner survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT clausgarbe survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma AT benjaminweide survivalaccordingtobrafv600tumormutationsananalysisof437patientswithprimarymelanoma |
_version_ |
1725095774392418304 |